英諾激光(301021.SZ):2024年上半年激光器業務實現營收1.44 億元,同比增長48.52%,毛利率為54.38%
格隆匯9月18日丨英諾激光(301021.SZ)在投資者關係中表示,公司 2024 年上半年激光器業務實現營收 1.44 億元,同比增長 48.52%,毛利率為 54.38%。歷年來的激光器毛利率保持穩定,凸顯了公司的產品和品牌的競爭力。去年,公司在納秒紫外激光器保持領先優勢的基礎上,加大了高端產品佈局,包括超快激光器、深紫外激光器,拓展光伏、半導體等市場,帶動了毛利率提升。
同時,公司注重領先的技術優勢轉化為成本控制能力,依託研發設計優化來降低成本,保障了毛利率穩定在較高水平。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.